Efficacy of Mirikizumab in Comparison to Ustekinumab in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3 VIVID-1 Study - Jairath, V.; Sands, B. E.; Bossuyt, P.; Farraye, F.; Ferrante, M.; Hisamatsu, T.; Kaser, A.; Kierkus, J.; Laharie, D.; Reinisch, W.; Siegmund, B.; Bragg, S. M.; Hon, E.; Lin, Z.; Lopes, M. U.; Morris, N.; Protic, M.; Danese, S. (Zeitschrift für Gastroenterologie, 2024)